RBPJL and esophageal squamous cell carcinoma: Given the exceptional clinical response of an ESCC patient with shrinkage of the primary oesophageal tumor and lung metastasis, and the enlargement of liver metastatic lesions after toripalimab monotherapy, we investigated and identified the p.P476S mutation of RBPJL as the genomic alteration responsible for the insensitive response of liver metastatic lesions to toripalimab therapy.